Citation
Hulgan, Todd, et al. "CD4 Lymphocyte Percentage Predicts Disease Progression in HIV-infected Patients Initiating Highly Active Antiretroviral Therapy With CD4 Lymphocyte Counts >350 Lymphocytes/mm3." The Journal of Infectious Diseases, vol. 192, no. 6, 2005, pp. 950-7.
Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis. 2005;192(6):950-7.
Hulgan, T., Raffanti, S., Kheshti, A., Blackwell, R. B., Rebeiro, P. F., Barkanic, G., Ritz, B., & Sterling, T. R. (2005). CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. The Journal of Infectious Diseases, 192(6), 950-7.
Hulgan T, et al. CD4 Lymphocyte Percentage Predicts Disease Progression in HIV-infected Patients Initiating Highly Active Antiretroviral Therapy With CD4 Lymphocyte Counts >350 Lymphocytes/mm3. J Infect Dis. 2005 Sep 15;192(6):950-7. PubMed PMID: 16107946.
TY - JOUR
T1 - CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
AU - Hulgan,Todd,
AU - Raffanti,Stephen,
AU - Kheshti,Asghar,
AU - Blackwell,Robert B,
AU - Rebeiro,Peter F,
AU - Barkanic,Gema,
AU - Ritz,Brandon,
AU - Sterling,Timothy R,
Y1 - 2005/08/15/
PY - 2004/08/30/received
PY - 2005/04/27/accepted
PY - 2005/8/19/pubmed
PY - 2005/11/9/medline
PY - 2005/8/19/entrez
SP - 950
EP - 7
JF - The Journal of infectious diseases
JO - J Infect Dis
VL - 192
IS - 6
N2 - BACKGROUND: The optimal timing of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected patients with > or = 200 absolute CD4 lymphocytes/mm3 is unknown. CD4 lymphocyte percentage could add prognostic information. METHODS: Persons who initiated HAART between 1 January 1998 and 1 January 2003, received > or = 30 days of therapy, and had baseline CD4 lymphocyte data available were included in the study. The log-rank test for time to event and Cox proportional hazards models were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or death. RESULTS: A total of 788 patients met the inclusion criteria. At baseline, subjects had a median of 225 CD4 lymphocytes/mm3 and 17% CD4 lymphocytes. Subjects with < 17% CD4 lymphocytes had earlier disease progression, compared with subjects with > or = 17%, both in the entire cohort (P<.0001) and of those subjects with > 350 absolute CD4 lymphocytes/mm3 at baseline (P=.03). CD4 lymphocyte percentage < 17% was the strongest predictor of disease progression among subjects in this latter group (hazard ratio, 3.57; P=.045). CONCLUSIONS: In this cohort, CD4 lymphocyte percentage predicted disease progression in HIV-infected subjects who initiated therapy with > 350 CD4 lymphocytes/mm3. This information may help identify persons who will derive the greatest benefit from initiation of HAART.
SN - 0022-1899
UR - https://www.unboundmedicine.com/medline/citation/16107946/CD4_lymphocyte_percentage_predicts_disease_progression_in_HIV_infected_patients_initiating_highly_active_antiretroviral_therapy_with_CD4_lymphocyte_counts_>350_lymphocytes/mm3_
L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/432955
DB - PRIME
DP - Unbound Medicine
ER -